331 related articles for article (PubMed ID: 24296321)
1. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
Lindblad AS; Manukyan Z; Purohit-Sheth T; Gensler G; Okwesili P; Meeker-O'Connell A; Ball L; Marler JR
Clin Trials; 2014 Apr; 11(2):205-17. PubMed ID: 24296321
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
3. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature.
Seife C
JAMA Intern Med; 2015 Apr; 175(4):567-77. PubMed ID: 25664866
[TBL] [Abstract][Full Text] [Related]
4. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
5. Application of methods for central statistical monitoring in clinical trials.
Kirkwood AA; Cox T; Hackshaw A
Clin Trials; 2013 Oct; 10(5):783-806. PubMed ID: 24130202
[TBL] [Abstract][Full Text] [Related]
6. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.
Rising K; Bacchetti P; Bero L
PLoS Med; 2008 Nov; 5(11):e217; discussion e217. PubMed ID: 19067477
[TBL] [Abstract][Full Text] [Related]
7. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
[TBL] [Abstract][Full Text] [Related]
8. Comparing methods for clinical investigator site inspection selection: a comparison of site selection methods of investigators in clinical trials.
Hein N; Rantou E; Schuette P
J Biopharm Stat; 2019; 29(5):860-873. PubMed ID: 31462145
[No Abstract] [Full Text] [Related]
9. U.S. Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009.
Morgan-Linnell SK; Stewart DJ; Kurzrock R
Clin Cancer Res; 2014 Jul; 20(13):3364-70. PubMed ID: 24737548
[TBL] [Abstract][Full Text] [Related]
10. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses.
Hart B; Lundh A; Bero L
BMJ; 2012 Jan; 344():d7202. PubMed ID: 22214754
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of clinical investigations; availability of guideline--FDA. Notice.
Fed Regist; 1988 Feb; 53(31):4723-4. PubMed ID: 10285639
[TBL] [Abstract][Full Text] [Related]
12. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
13. A clinical trial primer: historical perspective and modern implementation.
Karsh LI
Urol Oncol; 2012; 30(4 Suppl):S28-32. PubMed ID: 22795078
[TBL] [Abstract][Full Text] [Related]
14. Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study.
Brosteanu O; Schwarz G; Houben P; Paulus U; Strenge-Hesse A; Zettelmeyer U; Schneider A; Hasenclever D
Clin Trials; 2017 Dec; 14(6):584-596. PubMed ID: 28786330
[TBL] [Abstract][Full Text] [Related]
15. Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency.
Sellers JW; Mihaescu CM; Ayalew K; Kronstein PD; Yu B; Ning YM; Rodriguez M; Williams L; Khin NA
Ther Innov Regul Sci; 2022 Sep; 56(5):753-764. PubMed ID: 35610469
[TBL] [Abstract][Full Text] [Related]
16. Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018.
Heyward J; Moore TJ; Chen J; Meek K; Lurie P; Alexander GC
Ann Intern Med; 2020 Dec; 173(12):956-963. PubMed ID: 32986486
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials integrity: a CRO perspective.
Beach JE
Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
[TBL] [Abstract][Full Text] [Related]
18. Operation of a radiopharmacy for a clinical trial.
Norenberg JP; Petry NA; Schwarz S
Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
Romano CA; Nair S; Delphin ES
Anesth Analg; 2018 Mar; 126(3):976-982. PubMed ID: 29239950
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the effectiveness of a risk-based monitoring approach implemented with clinical trials involving implantable cardiac medical devices.
Diani CA; Rock A; Moll P
Clin Trials; 2017 Dec; 14(6):575-583. PubMed ID: 28819983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
